Paper - WANFANG MED ONLINE

You Position: Home > Paper

Novel agents for multiple myeloma bone disease

( views:280, downloads:230 )

Author:: No author available

Journal Title:: Journal of Leukemia & Lymphoma

Issue:: 2

DOI:: 10.3760/cma.j.issn.1009-9921.2014.02.020

Key Word:: 多发性骨髓瘤;骨病;新药;Multiple myeloma;Bone disease;Novel agent

Abstract： Bone disease is a major morbidity factor in patients with multiple myeloma and significantly affects their overall survival.A complex interplay between malignant plasma cells and other marrow cells results in the generation of a microenvironment to enhance both tumor growth and bone destruction.Bisphosphonates have consistently reduced the incidence of skeletal-related events in patients with multiple myeloma.However,their use is burdened with side-effects,including the risks of osteonecrosis of the jaw and kidney failure,suggesting that they should be discontinued after prolonged administration.New molecular targets of cell cross-talk in myeloma bone marrow are therefore under intensive investigation and new drugs are exploring in preclinical and clinical studies of myeloma bone disease.This review would focus on novel agents in myeloma bone disease.

Reference

[1]Masarachia PJ,Duong LT,Leung P,etc.The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.[J].2011,49(4).
[2]Yu-Tzu, Tai,Kenneth C, Anderson.Antibody-based therapies in multiple myeloma.[J].2011,2011.
[3]Wang J,Scagliotti GV,Costa L,etc.Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.[J].2011,29(9).
[4]E Michael, Lewiecki.Sclerostin: a novel target for intervention in the treatment of osteoporosis.[J].2011,12(65).
[5]Navas TA,Anderson KC,Kerr I,etc.Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.[J].2006,20(6).
[6]Kramer W,Jacobs M,Ruckle J.Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.[J].2009,24(4).
[7]Kostenuik PJ.Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.[J].2005,5(6).
[8]Kraenzlin ME,Meier C.Parathyroid hormone analogues in the treatment of osteoporosis.[J].2011,7(11).
[9]Rossi JF.Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenstrom's macroglobulinemia.[J].2011,11(1).
[10]Karin M,Lin A.NF-kappaB at the crossroads of life and death.[J].2002,3(3).
[11]Kyoko, Takeuchi,Masahiro, Abe,Masahiro, Hiasa,etc.Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.[J].2010,5(3).
[12]Siegel,R.,Ward,E.,Brawley,O.,etc.Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J].2011,61(4).
[13]Raab MS,Podar K,Breitkreutz I.Multiple myeloma.[J].2009,374(9686).
[14]Dai Y,Kramer LB,Dent P,etc.Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.[J].2011,117(6).
[15]Lorusso V,Marech I,Gnoni A,etc.Dasatinib: an anti-tumour agent via Src inhibition.[J].2011,12(4).
[16]Mieth M,Hecht M,Kaiser M,etc.Bortezomib inhibits human osteoclastogenesis.[J].2007,21(9).
[17]Kiziltepe T,Steed P,Hall S,etc.SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.[J].2009,113(4).
[18]Longxiang Shen,Xuetao Xie,Yan Su,etc.Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials.[J].2011,6(10).
[19]Matsumoto T,Abe M.TGF-beta-related mechanisms of bone destruction in multiple myeloma.[J].2011,48(1).
[20]Delaisse JM,Engsig MT,Karsdal M,etc.RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism.[J].2003,278(49).
[21]Marchetti L,Agas D,Coffin JD,etc.Endogenous FGF-2 is critically important in PTH anabolic effects on bone.[J].2009,219(1).
[22]Gnoni A,Di-Renzo N,Neri P,etc.Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.[J].2008,112(4).
[23]Zangari M,Suva LJ,Ranganathan S,etc.A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.[J].2011,96(2).
[24]Gupta A,Andreeff M,Klopp AH,etc.Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?[J].2011,29(1).
[25]Catley L,Anderson KC,Stirling DI,etc.Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.[J].2003,17(1).
[26]Khalid S, Mohammad,Carol G, Chen,Guive, Balooch,etc.Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.[J].2009,4(4).
[27]Yamori Y,Ikeda K,Kawai Y,etc.Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats.[J].2000,46(2).
[28]Wehmeyer O,Boyde A,von-Figura K,etc.Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.[J].1998,95(23).
[29]Angela, Pennisi,Wen, Ling,Xin, Li,etc.Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.[J].2010,5(12).
[30]Vallet, S,Mukherjee, S,Vaghela, N,etc.Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease[J].2010,107(11).
[31]Suva Larry J,Khan Sharmin,Barlogie Bart,etc.Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.[J].2009,145(6).
[32]Di Raimondo F,Merchionne F,Ribatti D,etc.Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.[J].2002,87(8).
[33]Kawano Y.,Kypta R..Secreted antagonists of the Wnt signalling pathway[J].2003,116(13).
[34]Voit S.,Teti A.,Boyce BF.,etc.Decreased c-Src expression enhances osteoblast differentiation and bone formation[J].2000,151(2).
[35]Tucci M,De Palma R,Lombardi L.beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells.[J].2009,69(16).